Vincere Biosciences Inc
2:30 PM - 2:45 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104C
Vincere Biosciences is developing AI-derived mitochondrial targeted therapeutics with a mission to conquer age-related decline.
Our lead assets are highly selective small molecules that increase mitophagy with application to Parkinson's disease, several cardiorenal indications, and more.
Our lead assets are highly selective small molecules that increase mitophagy with application to Parkinson's disease, several cardiorenal indications, and more.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
USP30 inhibitor targeting cardiorenal indications
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
